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FIG 2. Proliferative response of PBMCs. PBMCs were stimulated with
antigen (10 mg/mL) for 3 days. After incubation for an additional 16 hours
with [3H]-thymidine, [3H]-thymidine incorporation was measured. Statisti-
cal significance versus Cha o 3 was evaluated using Dunnett test
(*P < .01). The complementary DNA sequence of Cha o 3 was deposited
in the GenBank sequence database under accession number HV942721.
rCha o 2, recombinant Cha o 2; SBP, Sugi basic protein.
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LETTERS TO THE EDITOR 913for improving the efficacy of ASIT throughout the cypress pollen
season. Moreover, the present results suggest the presence of a
previously undescribed allergen in Japanese cedar pollen. We
hope the discovery of Cha o 3 will contribute to the development
of basic research and approaches for treating Japanese cedar,
cypress, and Cupressaceae pollinosis.
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http://dx.doi.org/10.1016/j.jaci.2016.03.026Anaphylactic reactions associated
with omalizumab administration:
Analysis of a case-control studyTo the Editor:
Treatment with omalizumab is associated with a small risk of
anaphylaxis (;0.2%). To clarify the circumstances and risk
factors associated with anaphylaxis to omalizumab,1 we conduct-
ed a case-control study comparing cases with an adjudicated
history of anaphylaxis to omalizumab with controls without a
history of anaphylaxis (X-PAND study; ClinicalTrials.gov
identifier NCT00813748 March 27, 2009, to April 3, 2014; see
Methods and Fig E1 available in this article’s Online Repository
at www.jacionline.org). An evaluation of the association between
the presence of antitherapeutic antibodies (ATAs) and the risk of
anaphylactic reactions among patients with previous omalizumab
exposure was included. An optional skin prick and intradermal
testing substudy was offered using a previously published
protocol.2
Clinical histories for 30 consenting patients with a history of
adjudicated anaphylaxis associated with omalizumab treatment
(cases) were region matched to 88 consenting and current/former
omalizumab-treated patients without anaphylaxis to omalizumab
(controls). Anaphylaxis reactions were identified using a standard
Medical Dictionary for Regulatory Activities query for all
anaphylactic events from clinical studies and postmarketing
reports. Cases eligible for the repository included those positively
adjudicated and deemed causally related by an independent
clinical expert (Phillip L. Lieberman) applying Sampson criteria,3
including the temporal association between omalizumab
administration and the event. Controls received 1 or more doses
of omalizumab within 18 months either before or after the
matching case’s first anaphylactic event and could not have had
prior anaphylaxis or other hypersensitivity reactions to omalizu-
mab. At least 1 control must have discontinued omalizumab treat-
ment to ensure an adequate washout period for omalizumab (ie,
16 wk/;4.5 elimination half-lives) for interpretable ATA data.
FIG 1. Kaplan-Meier time to anaphylaxis based on lifetime omalizumab
doses.
TABLE I. Demographic and baseline characteristics
Characteristic
Cases of
anaphylaxis
(n 5 30)
Controls
(n 5 88)
Mean 6 SD age at time of event (y)* 42.7 6 16.4 45.4 6 15.4
Sex: female, n (%) 27 (90.0) 60 (68.2)
Race, n (%)
White 26 (86.7) 62 (70.5)
Black 1 (3.3) 10 (11.4)
Asian 0 2 (2.3)
Other 3 (10.0) 14 (15.9)
Geographic region, n (%)
West 10 (33.3) 33 (37.5)
Midwest 7 (23.3) 19 (21.6)
Northeast 6 (20.0) 12 (13.6)
South 7 (23.3) 24 (27.3)
Mean 6 SD preomalizumab
IgE (IU/mL)
317.9 6 416.0 455.5 6 758.5
Mean 6 SD best FEV1 (%) 79.3 6 15.9 82.9 6 15.9
History of anaphylaxis or
anaphylactoid episode, n (%)
17 (56.7) 20 (22.7)
Mean 6 SD age at asthma diagnosis (y) 23.7 6 19.5 20.2 6 17.4
Omalizumab frequency, n (%)
Every 2 wk 16 (53.3) 40 (45.5)
Every 4 wk 13 (43.3) 40 (45.5)
Mean 6 SD total no. of
omalizumab doses§
18.6 6 19.6 58.5 6 59.7
History of allergies/allergic rhinitis, n (%) 29 (96.7) 86 (97.7)
History of food allergies, n (%) 18 (60.0) 33 (37.5)
History of allergic reaction following
any injection, n (%)
10 (33.3) 18 (20.5)
*For controls, age at the time of event was the age at the time of the adjudicated event
experienced by the matched control.
Cases, n 5 28; controls, n 5 83.
Cases, n 5 20; controls, n 5 79.
§Total number of omalizumab doses taken during their lifetime up to the day of the event
for cases and up to the day of enrollment for controls; cases, n5 28; controls, n 5 84.
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to give 79% power to detect a 4-fold increase in the risk for an
anaphylactic reaction assuming a 10% prevalence for an
identified risk factor and a 5% type I error (2-tailed). Prespecified
potential clinically meaningful risk factors (eg, presence of food
allergy, preomalizumab IgE levels, asthma severity, sex, and age)
were assessed for effect on the frequency of anaphylaxis. The
odds ratio (OR) was estimated for each risk factor using
conditional logistic regression models with 95% CI calculated
using Wald approximation. All analyses were performed using
SAS version 9.2 (SAS Institute Inc, Cary, NC).
All cases (n5 30) and 97.7% (n5 86) of the controls received
omalizumab for asthma. Controls had 3 times as many omalizu-
mab doses as did cases, indicating that we were comparing one
population that tolerated omalizumab to another that did not.
Most cases of anaphylaxis (24 of 30; 80%) included symptoms
categorized as cutaneous/subcutaneous/mucosal (ie, lips, tongue,
palate, uvula) and respiratory (ie, nose, laryngeal, lung). Most
(70.0%) events occurred within 1 hour of omalizumab dosing
(only 1 event occurred after 2 hours [ie, at 3.5 hours]). Median
(range) time from the last dose of omalizumab to the anaphylactic
event was 30 (0-210) minutes. Eleven of 28 (39.3%) patients in
whom the number of previous doses had been recorded
experienced anaphylaxis within the first 3 doses of omalizumab;
anaphylaxis occurred after 4 to 20 doses in 8 (28.6%) cases and
after more than 20 doses in 9 cases (1 case after >60 injections).
Fig 1 provides a Kaplan-Meier plot of the time to anaphylaxis
correlated to known lifetime doses of omalizumab.
None of the anaphylactic events resulted in disability or death.
Anaphylactic events were considered life-threatening in 12 of
30 (40.0%) cases and required hospitalization in another 6
(20.0%) cases. Treatment of anaphylaxis included the use of
antihistamines (23 of 30; 76.7%), epinephrine (21 of 30; 70.0%),
systemic corticosteroids (19 of 30; 63.3%), and inhaled
b-agonists (13 of 30; 43.3%).
No ATAs of IgG or IgE isotypes were detected among those
eligible for ATA analysis (21 cases; 10 controls). None of the
cases had a positive skin reaction to omalizumab or to excipient
alone versus 2 of 7 controls (skin prick test; diluted 1:1,000,
1:100, 1:10, and undiluted: intradermal; diluted 1:100,000).
Most patients in both groups were white and female, and more
of the cases of anaphylaxis reported a history of anaphylaxis
unrelated to omalizumab (56.7% vs 22.7%) and food allergies(60.0% vs 37.5%) compared with controls, respectively (Table I).
Bivariate conditional logistic regression analysis indicated that
among omalizumab users, a history of anaphylaxis to food,
medication, or other causes increased the subsequent risk of
anaphylaxis associated with omalizumab use (OR, 8.1; 95% CI,
2.7-24.3). The US Food and Drug Administration examined this
information and advised including it in an updated Xolair US
package insert. Total number of omalizumab doses, food
allergies, female sex, presence of urticaria/hives, and race also
were identified as potential risk factors for anaphylaxis associated
with omalizumab. The absolute risks for anaphylaxis may be
estimated on the basis of overall risks of 0.1% (based on clinical
trial data) or 0.2% (based on postmarketing reports) of users.
Assuming an overall 0.2% risk, the absolute increase in risk can
be indirectly estimated from the OR, and it would be
approximately 0.62% for patients with a history of anaphylaxis
and 0.08% for patients with no history of anaphylaxis, resulting
in a risk difference (ie, attributable risk) of 0.54%.
It should be noted that the overall incidence in our study
population of a history of anaphylaxis was higher than in the
general population.4,5 However, in a study of nearly 8000 patients
with moderate to severe asthma, a history of anaphylaxis was also
frequent (;22%), similar to the frequency observed in our control
subjects. In our sample, the reasons for the high frequency of a
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true risk for subsequent anaphylaxis in patients treated with oma-
lizumab or may be because these histories of anaphylaxis were
not adjudicated and may be subject to recall bias, or because we
evaluated a highly selected atopic population with asthma. These
are key limitations of this small case-control study. Nevertheless,
the results of our investigation are consistent with previous
studies indicating that the likelihood of anaphylaxis in general
is increased in patients with a history of asthma6,7 or with a history
of anaphylaxis.7
In our study, we found that anaphylaxis occurred most
frequently within the first 3 doses and within 1 hour of dosing.
In contrast, in a previous analysis, a delay between the
administration of omalizumab and the onset of anaphylaxis was
observed.1 This delay prompted the suggestion of prolonged in
office observation times.8 The reasons for this discrepancy
between the current and previous studies are not apparent, but
our observations indicate that it would be worthwhile to continue
to collect data to see whether the prolonged observation time is
justified. As in previous observations, we found no evidence
to support an immunologic pathogenesis, specifically an IgE-
mediated event, underlying anaphylactic episodes due to the
administration of omalizumab.2,9,10 Although the mechanism
causing these events remains unknown, the possibility that they
are due to a reaction to polysorbate, an excipient in the prepara-
tion, has been suggested9,10 and cannot be ruled out.
Although anaphylaxis associated with omalizumab remains a
rare event, when prescribing omalizumab health care providers
should consider these observations along with the clinical
benefits, and should adhere to recommended clinical guidance
regarding monitoring for anaphylaxis.8
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increased in patients with active
pediatric eosinophilic esophagitisTo the Editor:
Eosinophilic esophagitis (EoE) is a chronic, food antigen–
driven gastrointestinal disease characterized by marked
esophageal eosinophilia. CCL26 (eotaxin-3) levels mediate
eosinophil tissue recruitment,1,2 and eosinophil tissue counts
serve as the basis for diagnosis.3 Currently, EoE treatment
efficacy is often determined through invasive serial endoscopies
with esophageal biopsies; thus, there is a compelling need to
develop novel and less-invasive blood-based biomarkers to
evaluate EoE disease activity. Although peripheral blood
eosinophil counts moderately correlate with esophageal tissue
eosinophil levels, their relationship is not sufficient to serve as a
clinically useful biomarker.4
Similar to the mature eosinophil, the lineage-committed
eosinophil progenitor (EoP) is mobilized during allergic disease.5
EoP frequency is increased in the peripheral blood of adult pa-
tients with asthma in response to allergen challenge.6,7 Also,
EoP levels are increased in the lung tissue and sputum of
allergen-challenged patients with asthma, suggesting a direct
contribution to tissue eosinophilia through in situ differentiation
after migration from the peripheral blood.6,8 Notably, peripheral
blood EoP levels correlate with the severity of asthma in adults,
advancing the concept of the EoP as a clinically useful
biomarker.6
No clinical studies to date have measured EoP levels in patients
with EoE.We hypothesized that EoP levels would be increased in
the peripheral blood of pediatric patients with active EoE disease
and would correlate sufficiently with the level of mature
eosinophils in the esophagus to serve as a relevant biomarker
for EoE disease activity.
To test our hypothesis, peripheral blood samples for EoP
enumeration were obtained from consented pediatric patients
(Table I) undergoing endoscopy for evaluation of EoE at the
Cincinnati Center for Eosinophilic Disorders (Cincinnati
Children’s Hospital Medical Center). Included subjects were
aged 1 to 18 years and had a diagnosis of EoE. Patients met the
consensus criteria for EoE and experienced proton pump inhibitor
therapy failure, which serves as part of the diagnostic criteria of
EoE.3 Patients were excluded if other inflammatory
METHODS
The clinical data and serum repository was initiated on March 27, 2009,
and closed on April 3, 2014 (ClinicalTrials.gov identifier NCT00813748).
This study was conducted in accordance with US Food and Drug
Administration regulations, the International Conference on Harmonisation
E6 Good Clinical Practice guidelines, and applicable local, state, or federal
laws. Institutional review board approval and informed consent were
obtained for study participation. The health care provider (HCP) for each
identified anaphylaxis case was instrumental in obtaining informed consent.
The HCP for each positively adjudicated anaphylaxis case was asked to
identify from the practice up to 4 current or former omalizumab-treated
patients without anaphylaxis and/or hypersensitivity reactions to
omalizumab to serve as control subjects. If 4 control patients could not
be identified, supplementary controls from the same geographic region as
the case were recruited.
The primary exposure of interest for the repositorywas the detection ofATAs
to omalizumab in all patients. Patients were evaluated by their HCP. Following a
screening visit, the enrollment visit included data collection (demographic
characteristics, clinical characteristics, anaphylaxis description [anaphylaxis
cases only], history of hypersensitivity reactions, medication history, drug and
allergy information) and a 5-mL blood sample for the ATA assay and IgE and
IgG isotypes (anaphylaxis cases and assay controls). The presence of
antiomalizumab IgG antibodies was determined using 2 omalizumab frag-
ment–specific ELISAs using either the Fab or Fc fragment of omalizumab as the
capture agent (Bureco AG, Reinach, Switzerland). An ELISAwas designed to
distinguish between bound and unbound omalizumab by IgE (Bureco AG) to
account for the high affinity of omalizumab for the Fc fragment of human IgE.
Because of omalizumab’s mechanism of action, its effect on blunting skin test
reactivity, and interference with the assay to detect ATAs against omalizumab,
serum sample collections for the repository database were conducted at least
16 weeks after discontinuation of omalizumab to allow for washout of the drug.
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Not evaluable
(n=151)
Assessed for eligibility (n=1,199)
Did not meet criteria for adjudication or
previously adjudicated (n=122) 
Submitted to the
adjudicator (n=1,077) 
Positively adjudicated
(n=162) 
Negatively adjudicated
(n=611) 
Duplicate cases submitted
in error (n=153) 
Enrolled
(n=30) 
No enrollment
(n=132) 
FIG E1. Disposition of anaphylaxis cases.
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